QCG
CBIO

Quadrant Capital Group’s Crescent Biopharma CBIO Stock Holding History

Quadrant Capital Group’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1
Closed – – 2327
2020
Q3 		$0 Hold
1
– – ﹤0.01% 2218
2020
Q2 		$0 Buy
+1
New +$283 ﹤0.01% 2286

Other funds holding CBIO

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Quadrant Capital Group's CBIO Position: Q4 2020 in Review

Quadrant Capital Group sold out of Crescent Biopharma (CBIO) in Q4 2020, closing a stake of 1 share.

Quadrant Capital Group first reported a position in CBIO in Q2 2020 and held it in 2 quarters. The position peaked at $0 in Q3 2020. 89 funds tracked by Wall St. Rank hold CBIO as of Q4 2020.

  • Quadrant Capital Group reported no remaining Crescent Biopharma position as of Q4 2020 after selling out during the quarter.
  • Quadrant Capital Group sold 1 Crescent Biopharma share in Q4 2020.
  • Quadrant Capital Group first reported a position in Crescent Biopharma in Q2 2020 and held it in 2 quarters.
  • Quadrant Capital Group's Crescent Biopharma position peaked at $0 in Q3 2020.
  • 89 funds tracked by Wall St. Rank held Crescent Biopharma as of Q4 2020.

Based on Quadrant Capital Group's 13F filing for Q4 2020, filed 16 Feb 2021.